Comment on Forget Tilray, These Two Biotech Stocks Have Far More Upside

Forget Tilray, These Two Biotech Stocks Have Far More Upside

Canada's Tilray (NASDAQ: TLRY), a marijuana cultivator and distributor, has given early investors the ride of their lives since going public last June. Last week, for instance, the company's stock peaked at exactly $300 per share, representing a jaw-dropping 856% gain for the brave souls that bought this speculative IPO right off the bat. Even though Tilray's shares have pulled back in a big way since reaching this gravity-defying peak a few days ago, the pot grower's valuation remains wildly disconnected from its near-term growth prospects.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News